Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

  1. Home

  • Sunday, Oct 26th
    10:30 AM - 11:30 AM Central Time
    26S25: Tackling the Burning Question of Peripheral Neuropathies in Sjögren's Disease: New Guidelines
    Location: W181A-C
    Moderator: Jennifer King, MD, PhD – UCLA
    Moderator: Dana DiRenzo, MD, RhMSUS, MHS – University of Pennsylvania
    Session Coordinator: Jennifer Grossman, MD – UCLA
     CE: 1.00
  • Sunday, Oct 26th
    10:30 AM - 11:00 AM Central Time
    Guidelines for Peripheral Nervous System Disorders in Sjögren's
    Location: W181A-C
    Speaker: R. Scofield, MD – Oklahoma Medical Research Foundation
  • Sunday, Oct 26th
    11:00 AM - 11:30 AM Central Time
    Case-Based Approach to Guidelines
    Location: W181A-C
    Speaker: Arun Varadhachary, MD,PhD – Washington University in St. Louis
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    Sjögren’s Disease – Basic & Clinical Science Poster I: Etiology, Pathogenesis, Diagnosis
    Location: Hall F1
     CE: 0.00
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0514: Transitional Monocytes and Innate T Cell Populations Help Distinguish Ro Seropositive vs Ro Seronegative Sjögren’s Disease Using Whole Blood Immunophenotyping
    Location: Hall F1
    Abstract Poster Presenter: Nicholas Bauer, BS – Oklahoma Medical Research Foundation
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0518: Deregulation of PSGL-1, HLA-DR and IFNα expression in peripheral innate immune cells of primary Sjögren Syndrome patients
    Location: Hall F1
    Abstract Poster Presenter: Santos Castañeda, MD,PhD (he/him/his) – Hospital Universitario de La Princesa, IIS-Princesa
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0506: Discovery-based Identification of Non-canonical Autoantibody Specificities in Ro Seronegative Sjögren's Disease Using High-content Human Proteome Arrays
    Location: Hall F1
    Abstract Poster Presenter: A. Darise Farris, PhD – Oklahoma Medical Research Foundation
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0513: Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies
    Location: Hall F1
    Abstract Poster Presenter: Massiel Jimenez Artiles, MD (she/her/hers) – Rhode Island Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0510: A Risk Estimation Tool for Clinical Practice to Improve Early ILD Detection in Sjögren Disease
    Location: Hall F1
    Abstract Poster Presenter: Anna-Maria Hoffmann-Vold, MD, PhD – Oslo University Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0519: A Multi-criterion Feature Integration Framework for Accurate Diagnosis of Primary Sjögren's Syndrome Using Routine Laboratory Tests: A Multicentre, Retrospective Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Shu Liu, n/a – Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0511: Submandibular Gland Ratio Stratifies Salivary Function and Reveals a Senescence Peak in Anti-SSA Positive Sjögren’s Syndrome
    Location: Hall F1
    Abstract Poster Presenter: Chiao‐Feng Cheng, MD – National Taiwan University Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0521: Umbilical cord-derived mesenchymal stem cells suppress the pathogenesis of primary Sjögren's disease by inducing Bach2 expression
    Location: Hall F1
    Abstract Poster Presenter: Yukitomo Hagiwara, MD – Juntendo University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0507: Diagnostic performance of the lacrimal and salivary gland ultrasound in patients with primary Sjogren's disease of recent onset versus sicca controls.
    Location: Hall F1
    Abstract Poster Presenter: Daniela Rojas Abarca, MD, RhMSUS – Universidad Nacional Autonoma de Mexico
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0512: Dry Eye Disease Severity and Salivary Gland Biopsy in Patients with Primary Sjögren’s Syndrome
    Location: Hall F1
    Abstract Poster Presenter: Karina Palomo-Arnaud, MD – Universidad Autonoma de Nuevo Leon
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0516: Association Between Anti-cytosolic 5'-nucleotidase 1A (anti-cN1A) Antibodies and Lymphoma in Primary Sjögren Disease (SD)
    Location: Hall F1
    Abstract Poster Presenter: Pierre-Marie Duret, MD, MSc (he/him/his) – Colmar General Hospital; Strasbourg University Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0508: Serum immune complexes assessed using a cell-reporter assay are associated with serum IFN-alpha levels, disease activity and the risk of incident lymphoma in the ASSESS prospective cohort
    Location: Hall F1
    Abstract Poster Presenter: Jacques-Eric Gottenberg, PhD (he/him/his) – Hautepierre Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0517: Gut Microbiota Dysbiosis and Clinical Predictors of Fatigue in Primary Sjögren’s Syndrome: A Multi-Omics Study
    Location: Hall F1
    Abstract Poster Presenter: Qiguo Cui, MMed – Southern Medical Univercity
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0515: Inverse Correlation Between Type I Interferon Pathway Activation And Unstimulated Whole Salivary Flow In Sicca Patients
    Location: Hall F1
    Abstract Poster Presenter: Nikolaos Marketos, MD, MSc, PhD – Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Greece
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0520: Implementation of Salivary Gland Ultrasound by General Radiology can Improve Detection of Glandular Inflammation in Patients with Sicca
    Location: Hall F1
    Abstract Poster Presenter: Stephanie Lee, MD (she/her/hers) – University of Pennsylvania and Children's Hospital of Philadelphia
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0509: Functional Anti-M3R Autoantibodies in Sjögren’s Disease: From Gland to Circulation
    Location: Hall F1
    Abstract Poster Presenter: R. Hal Scofield, MD – Oklahoma Medical Research Foundation
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes
    Location: Hall F1
     CE: 0.00
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1380: Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
    Location: Hall F1
    Abstract Poster Presenter: Chiara Baldini, MD;PhD – University of Pisa
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1391: Assessment of Anti-ssa/ro Testing Across Various Commercial Laboratories in the United States to Reduce the Burden of Surveillance in Pregnant Women with No History of Fetal Atrioventricular Block (fAVB)
    Location: Hall F1
    Abstract Poster Presenter: Mala Masson, BA – NYU Langone Medical Center- Division of Rheumatology
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1392: Cancer Mortality in Sjogren’s Disease: Disproportionate Increase in Mortality from Cancers in Sjogren’s Disease Relative to All-Cancers
    Location: Hall F1
    Abstract Poster Presenter: Margaret Essien, Undergraduate – UCLA David Geffen School of Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1397: Cardiovascular And Cerebrovascular Risk In Sjögren’s Disease: Results From A Prospective Multicenter Cohort.
    Location: Hall F1
    Abstract Poster Presenter: Olga Rusinovich Lovgach, MD – Puerta de Hierro University Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1399: Significance of Antiphospholipid Antibodies in Patients with Sjogren’s Disease
    Location: Hall F1
    Abstract Poster Presenter: Rashmi Thimmapuram, MD (she/her/hers) – University of Kansas Medical Center
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1381: Self-Reported and Actigraphic Sleep and Circadian Rhythm Disruptions in Patients with Sjögren’s Disease: Associations with Disease Activity and Patient-Reported Outcomes
    Location: Hall F1
    Abstract Poster Presenter: Chiara Baldini, MD;PhD – University of Pisa
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1400: Beyond the Glands: Hypogammaglobulinemia as a Clue to Peripheral Neuropathy in Sjogren´s Disease
    Location: Hall F1
    Abstract Poster Presenter: Renata Lima, MD (she/her/hers) – UNICAMP
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1388: Positive predictive value of various diagnostic codes for the classification of primary Sjӧgren’s syndrome
    Location: Hall F1
    Abstract Poster Presenter: Kaci Clement, MD (she/her/hers) – Mayo Clinic
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1383: Obesity in Primary Sjogren’s Disease
    Location: Hall F1
    Abstract Poster Presenter: Gabriela Hernandez-Molina, MD, MS – Instituto Nacional de Ciencias Medicas y Nutricion
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1382: Interstitial lung disease in primary sjögren syndrome: pathochrony, seronegative cases, and Risk of progressive pulmonary fibrosis
    Location: Hall F1
    Abstract Poster Presenter: Delia Reina, MD, PhD – Complex Hospitalari Universitari Moisès Broggi
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1403: Treatment of sleep apnoea syndrome in patients with primary Sjögren’s disease improves symptoms and activity of disease
    Location: Hall F1
    Abstract Poster Presenter: Stephanie Finzel, MD (she/her/hers) – University Medical Center Freiburg
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1395: A Comparative Study of Yao Syndrome and Primary Sjögren's Syndrome
    Location: Hall F1
    Abstract Poster Presenter: Nayaab Bakshi, DO – Stony Brook University Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1377: Humanistic Burden of Sjögren's Disease: A Systematic Review of Treatment Efficacy on Health-Related Quality-of-Life
    Location: Hall F1
    Abstract Poster Presenter: Alexander Keenan, MPH, MA – Johnson & Johnson
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1376: A Systematic Literature Review on the Economic Burden of Sjögren's Disease
    Location: Hall F1
    Abstract Poster Presenter: Alexander Keenan, MPH, MA – Johnson & Johnson
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1389: Association of Dry Eye Severity with Salivary Flow in Patients with Primary Sjögren’s Syndrome
    Location: Hall F1
    Abstract Poster Presenter: Karina Palomo-Arnaud, MD – Universidad Autonoma de Nuevo Leon
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1398: Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health
    Location: Hall F1
    Abstract Poster Presenter: R. Mohamad Javier, n/a – University of Indonesia Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1393: Prevalence of Sjögren's Disease in the United States - A Retrospective Cohort Study Among a Commercially Insured Population (2019-2023)
    Location: Hall F1
    Abstract Poster Presenter: Minoti Ganguli, MPH – Amgen Inc.
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1385: Characterizing Isolated Dryness Phenotypes in Sjögren’s Syndrome
    Location: Hall F1
    Abstract Poster Presenter: Giovanni Fulvio, Sr, MD – University of Pisa
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1394: Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
    Location: Hall F1
    Abstract Poster Presenter: Minoti Ganguli, MPH – Amgen Inc.
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1396: Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren's Disease
    Location: Hall F1
    Abstract Poster Presenter: Nevsun Inanc, MD (she/her/hers) – Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1401: Real World Treatment Patterns and Health Care Resource Use in Patients With Newly Diagnosed Sjögren’s Disease (SjD) in the United States
    Location: Hall F1
    Abstract Poster Presenter: Sara McCoy, MD, PhD, RhMSUS – University of Wisconsin
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1404: Higher cardiovascular risk and lymphoma development in primary Sjögren's Syndrome with extraglandular involvement
    Location: Hall F1
    Abstract Poster Presenter: Teresa Blázquez Sánchez, Sr, MD – Fundación Jiménez Díaz Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1402: Understanding Fatigue Through Patients' Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren's Disease
    Location: Hall F1
    Abstract Poster Presenter: Saviana Gandolfo, MD – Rheumatology Unit, Ospedale del mare, Naples
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1379: Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort
    Location: Hall F1
    Abstract Poster Presenter: Biji T Kurien, PhD – Oklahoma Medical Research Foundation
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1387: Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network
    Location: Hall F1
    Abstract Poster Presenter: Jeffrey Curtis, MD, MS, MPH – University of Alabama at Birmingham
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1390: Cystic Lung Disease and Autoantibodies in Lymphocytic Interstitial Pneumonia: Exploring the Impact of Sjögren’s Syndrome
    Location: Hall F1
    Abstract Poster Presenter: Karla Chacon, MD (she/her/hers) – Instituto Nacional de Enfermedades Respiratorias
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1384: Systematic Review of Therapies for Central Nervous System Manifestations in Sjögren’s Disease
    Location: Hall F1
    Abstract Poster Presenter: Ghaith Noaiseh, MD – University of Kansas Medical Center
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1378: Prevalence of Central Nervous System Manifestations in Sjögren’s Disease
    Location: Hall F1
    Abstract Poster Presenter: Arun Varadhachary, MD,PhD – Washington University in St. Louis
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1386: Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.
    Location: Hall F1
    Abstract Poster Presenter: Hoang Nguyen, MD (he/him/his) – Stony Brook University
  • Monday, Oct 27th
    1:00 PM - 2:30 PM Central Time
    27M33: Abstracts: Sjögren’s Disease – Basic & Clinical Science
    Location: S103
    Abstract Moderator: Chiara Baldini, MD;PhD – University of Pisa
    Abstract Moderator: Alan Baer, MD, FACP, MACR – Johns Hopkins University School of Medicine
     CE: 0.00
  • Monday, Oct 27th
    1:00 PM - 1:15 PM Central Time
    1680: Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review
    Location: S103
    Presenting Author: Valeria Manfrè, MD – Division of Rheumatology, Department of Medicine, University of Udine, Italy; Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, WI
  • Monday, Oct 27th
    1:15 PM - 1:30 PM Central Time
    1681: Lymphoma and Other Malignancies in Sjögren’s Disease: Incidence, Predictive Factors, and Mortality Outcomes.
    Location: S103
    Presenting Author: Olga Rusinovich Lovgach, MD – Puerta de Hierro University Hospital
  • Monday, Oct 27th
    1:30 PM - 1:45 PM Central Time
    1682: Sjögren’s Disease Salivary Gland Fibroblast Subsets are Proinflammatory and Aberrantly Promote Pain
    Location: S103
    Presenting Author: Sara McCoy, MD, PhD, RhMSUS – University of Wisconsin
  • Monday, Oct 27th
    1:45 PM - 2:00 PM Central Time
    1683: Serum APRIL Is Associated With B-Cell Activation Markers, Disease Activity, and Lymphoma Risk in Sjögren Disease (SD): Data From the prospective ASSESS Cohort
    Location: S103
    Presenting Author: Pierre-Marie Duret, MD, MSc (he/him/his) – Colmar General Hospital; Strasbourg University Hospital
  • Monday, Oct 27th
    2:00 PM - 2:15 PM Central Time
    1684: Integration of Multiple Spatial Transcriptomics Reveals Novel Insights into Sjogren Disease Salivary Gland Fibroblast by Peripheral Serostatus
    Location: S103
    Presenting Author: Sara McCoy, MD, PhD, RhMSUS – University of Wisconsin
  • Monday, Oct 27th
    2:15 PM - 2:30 PM Central Time
    1685: The Sjögren’s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sjögren’s disease
    Location: S103
    Presenting Author: raphaele seror, MD,PhD – university hospital Paris Saclay
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    Sjögren’s Disease – Basic & Clinical Science Poster III: Treatment and Trial Outcome Measures
    Location: Hall F1
     CE: 0.00
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2290: Patterns and Predictors of Clinical Improvement in Patients with Sjögren’s Disease: A Longitudinal Analysis of ESSDAI and ESSPRI Improvements
    Location: Hall F1
    Abstract Poster Presenter: Alejandro Gómez Gómez, PhD – Hospital Universitari Vall d'Hebron
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2291: Correlation and Concordance Between the Oxford Grading Scale, Ocular Staining Score, and van BijsterveldScore in the diagnosis of Sjögren's Disease
    Location: Hall F1
    Abstract Poster Presenter: Alejandro Gómez Gómez, PhD – Hospital Universitari Vall d'Hebron
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2292: Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren's Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
    Location: Hall F1
    Abstract Poster Presenter: Ana Medeiros-Ribeiro, MD, PhD (she/her/hers) – Hospital das Clinicas da Faculdade de Medicina da USP
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2296: Evaluation of the Dual Mode of Action of Ianalumab (VAY736) in the Circulation and Salivary Gland Tissue of Patients With Sjögren’s Disease: Results From a Phase 2 Mechanistic Study
    Location: Hall F1
    Abstract Poster Presenter: Divi Cornec, MD PhD (he/him/his) – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2300: Evaluation of the Ianalumab Treatment Effects on Major Salivary Glands of Patients With Sjögren’s Disease by Multimodal Ultrasound: Results From a Phase 2 Mechanistic Study
    Location: Hall F1
    Abstract Poster Presenter: sandrine jousse joulin, MD – cavale blanche hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2302: Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease
    Location: Hall F1
    Abstract Poster Presenter: Thomas Grader-Beck, MD – Johns Hopkins
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2295: Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI
    Location: Hall F1
    Abstract Poster Presenter: Deepak Rath, MD, MBBS, DM – John H Stroger Hospital Jr of Cook County, Chicago, Illinois 60612
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2294: Comparative Analysis of Patients Included in Trials Utilizing Biologic Drugs in the Treatment of Primary Sjögren’s Syndrome
    Location: Hall F1
    Abstract Poster Presenter: Carlota Navarro Joven, -None- – Hospital Universitario de Fuenlabrada
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2301: Use of lived experiences in childhood Sjogren Disease to develop outcome measures for an N-of-1 treatment trial.
    Location: Hall F1
    Abstract Poster Presenter: Sara Stern, MD – University of Utah
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2297: Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjogren’s Disease Treated with Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study
    Location: Hall F1
    Abstract Poster Presenter: Faye Yu, BSc – Johnson & Johnson Innovative Medicine
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2303: Metabolic impact of low dose IL‐2 therapy for primary Sjögren’s Disease in a double‐blind, randomized clinical trial
    Location: Hall F1
    Abstract Poster Presenter: Yuebo Jin, MD – Peking University People's Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2298: When Imaging and Biopsy Disagree: Diagnostic Value of Doppler Ultrasound and Histologic Features beyond the Focus Score
    Location: Hall F1
    Abstract Poster Presenter: Kyung Ann Lee, MD, PhD (she/her/hers) – Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2299: Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive interstitial lung disease associated with primary sjögren’s syndrome
    Location: Hall F1
    Abstract Poster Presenter: Paula Valentina Estrada Alarcón, MD, PhD – H Moisès Broggi
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2293: CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
    Location: Hall F1
    Abstract Poster Presenter: Antoine Sreih, MD – Cullinan Therapeutics
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2304: Updates in the local treatments in Primary Sjögren's Syndrome “Efficacy and Safety”
    Location: Hall F1
    Abstract Poster Presenter: Marta Ramírez Martín, MD (she/her/hers) – Hospital University Principe de Asturias
  • Wednesday, Oct 29th
    10:00 AM - 11:00 AM Central Time
    29W09: Decoding Sjögren's Disease: Adaptive Immunity Driving Pathogenesis
    Location: W181A-C
    Moderator: Blake M. Warner, PhD;MPH;DDS – National Institutes of Health
    Moderator: Rachael Gordon, MD, PhD – University of Pittsburgh
    Session Coordinator: Teresa Tarrant, MD – Duke University
     CE: 1.00
  • Wednesday, Oct 29th
    10:00 AM - 10:30 AM Central Time
    Regulatory T Cells and IFN-γ-Producing Th1 Cells Play a Critical role in the Pathogenesis of Sjögren's Disease
    Location: W181A-C
    Speaker: Stefan Feske, MD – NYU Langone Health
  • Wednesday, Oct 29th
    10:30 AM - 11:00 AM Central Time
    What Causes Acinar Cell Dysfunction in Sjögren’s Disease? A Narrative Involving Fibroblast-mediated, Antigen-independent Activation of Tissue-resident CD8+ T-cells
    Location: W181A-C
    Speaker: Sarah Pringle, PhD – University Medical Center Groningen